R
Robert Yarchoan
Researcher at Research Triangle Park
Publications - 24
Citations - 1897
Robert Yarchoan is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Zidovudine & Virus. The author has an hindex of 11, co-authored 24 publications receiving 1879 citations. Previous affiliations of Robert Yarchoan include University of Miami & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of htlv-iii/lav replication, to patients with aids or aids-related complex
Robert Yarchoan,Kent J. Weinhold,H. Kim Lyerly,Edward P. Gelmann,Robert M. Blum,Gene M. Shearer,Hiroaki Mitsuya,Jerry M. Collins,Charles E. Myers,Raymond W. Klecker,Phillip D. Markham,David T. Durack,S. Nusinoff Lehrman,David W. Barry,Margaret A. Fischl,Robert C. Gallo,Dani P. Bolognesi,Samuel Broder +17 more
TL;DR: 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC).
Journal ArticleDOI
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.
Robert Yarchoan,Robert Yarchoan,Pim Brouwers,Pim Brouwers,A. Robert Spitzer,A. Robert Spitzer,Jordan Grafman,Jordan Grafman,Jordan Grafman,Bijan Safai,Bijan Safai,Carlo Federico Perno,Carlo Federico Perno,Steven M. Larson,Steven M. Larson,G. Berg,G. Berg,Margaret A. Fischl,Margaret A. Fischl,Margaret A. Fischl,Alison Wichman,Alison Wichman,Rose V. Thomas,Rose V. Thomas,Arturo Brunetti,Arturo Brunetti,Peter J. Schmidt,Peter J. Schmidt,Charles E. Myers,Charles E. Myers,Samuel Broder,Samuel Broder +31 more
TL;DR: The hypothesis that certain AIDS-virus-associated neurological abnormalities are reversible by antiretroviral chemotherapy is supported.
Journal ArticleDOI
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
Lauri Welles,MW Saville,Jill Lietzau,James M. Pluda,Kathleen M. Wyvill,I. Feuerstein,William D. Figg,Richard Lush,Jeanne Odom,Wyndham H. Wilson,M T Fajardo,R. W. Humphrey,Ellen Feigal,D Tuck,Seth M. Steinberg,Samuel Broder,Robert Yarchoan +16 more
TL;DR: Paclitaxel has substantial activity against advanced HIV-associated Kaposi's sarcoma as a single agent, even in patients with pulmonary involvement or who had previously received anthracyclines.
Journal ArticleDOI
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection
Philip A. Pizzo,Janie Eddy,J. Falloon,Frank M. Balis,Robert F. Murphy,Howard B. Moss,Pamela L. Wolters,Pim Brouwers,Paul Jarosinski,Mark A. Rubin,Samuel Broder,Robert Yarchoan,Arturo Brunetti,Mary Maha,S Nusinoff-Lehrman,David G. Poplack +15 more
TL;DR: AZT is beneficial in children with symptomatic HIV infection, especially those with encephalopathy (which may be subclinical), and that the optimal continuous intravenous dose of AZT in children is between 0.9 and 1.4 mg per kilogram per hour is concluded.
Journal ArticleDOI
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex
Paulo de Miranda,Steven S. Good,Robert Yarchoan,Rose V Thomas,M. Robert Blum,Charles E Myers,Samuel Broder +6 more
TL;DR: The mean zidovudine plasma levels were significantly higher after concurrent administration of probenecid than in its absence, resulting in a twofold increase in the mean AUC, a corresponding decline in the apparent total clearance, and a prolongation in themean half‐life.